IP Library Granted Patent US 8,088,735
Granted Patent B2
US 8,088,735 · App. 12/738,634 · Granted Jan 3, 2012

Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,735
App. No.
12/738,634
Granted
Jan 3, 2012
Kind
B2
Abstract

A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.

Claims (11)

1. A method of treating cancer in a subject in need thereof, the method comprising:

(a) determining an expression of PlexD1 receptor on cells of a tumor sample of the subject; and

(b) when an amount of said PlexD1 receptor is above a predetermined threshold, contacting cancerous cells of the subject with a therapeutically effective amount of pro-protein convertase resistant Semaphorin 3E thereby treating the cancer.

2. The method of claim 1 , wherein said contacting is effected by systemic administration.

3. The method of claim 1 , wherein said contacting is effected by local administration.

4. The method of claim 1 , wherein said cancer is selected from the group consisting of breast cancer, pancreatic cancer and lung cancer.

5. The method of claim 1 , wherein said detecting is effected using an antibody which is capable of identifying said PlexD1 receptor.

6. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pro-protein convertase resistant semaphorin 3E, thereby treating the cancer.

7. The method of claim 6 , wherein said administering comprises systemic administration.

8. The method of claim 6 , wherein said administering comprises local administration.

9. The method of claim 6 , wherein said cancer is selected from the group consisting of breast cancer, pancreatic cancer and lung cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2018
From: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
To: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Reel/Frame 046493/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2010
From: NEUFELD, GERA; KIGEL, BOAZ; KESSLER, OFRA; VARSHAVSKY, ASYA
To: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Reel/Frame 024334/0508 →